

- A4
10. (Amended) A method of inhibiting the growth of a refractory tumor capable of stimulation by a ligand of epidermal growth factor receptor (EGFR) in a human patient which comprises treating the human patient with a therapeutically effective amount of an EGFR/HER1 antagonist and radiation.

21. (Amended) A method according to claim 10 wherein the tumors are tumors of the breast, heart, lung, small intestine, colon, spleen, kidney, bladder, head and neck, ovary, prostate, brain, pancreas, skin, bone, bone marrow, blood, thymus, uterus, testicles, cervix, or liver.

22. (Amended) A method of inhibiting the growth of a refractory tumor capable of stimulation by a ligand of epidermal growth factor receptor (EGFR) in a human patient which comprises treating the human patient with a therapeutically effective amount of an EGFR/HER1 antagonist and a chemotherapeutic agent.

- A6
32. (Amended) A method according to claim 22 wherein the tumors are tumors of the breast, heart, lung, small intestine, colon, spleen, kidney, bladder, head and neck, ovary, prostate, brain, pancreas, skin, bone, bone marrow, blood, thymus, uterus, testicles, cervix, or liver.

Please add the following new claims:

- AM
34. A method of inhibiting the growth of a refractory tumor capable of stimulation by a ligand of epidermal growth factor receptor (EGFR) in a human patient which comprises treating the human patient with a therapeutically effective amount of an EGFR/HER1 antagonist, wherein said refractory tumor has been treated with radiation, chemotherapy, or combinations thereof.
35. A method of inhibiting the growth of a refractory tumor capable of stimulation by a ligand of epidermal growth factor receptor (EGFR) in a human patient which comprises treating the human patient with a therapeutically effective amount of an EGFR/HER1 antagonist, wherein said refractory tumor has been treated with therapy selected from the group consisting of radiation, chemotherapy, and combinations thereof, and further wherein said therapy failed to produce a complete or partial response in the tumor.

REMARKS

Claims 1, 8, 10, 21, 22, and 32 have been amended and new claims 34 and 35 have been added. The amendments are identical to those made in parent application 09/374,028 in an Amendment Under 37 C.F.R. §1.111 on August 3, 2000. The new